Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Liberté stents for de novo native coronary stenosis

Ishikawa, Takahiro; Nakano, Yukiko; Hino, Shoryoku; Suzuki, Takahiko; Murakami, Akimichi; Tsutsumi, Joshi; Miyamoto, Takashi; Murata, Makoto

doi:10.1016/j.jjcc.2013.05.003

Cited by 4 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date only a single study has performed a similar analysis using a metallic DES platform. In their report, Ishikawa et al [13] compared outcomes between the TAXUS Liberte and TAXUS Express stent platform, finding no differences in either patient outcomes or in the incidence of binary ISR. Similar to our study, the difference in the platforms was solely in stent design, with the Liberte stent having a thinner strut and greater spacing to improve homogeneity of drug delivery.…”

Section: Discussionmentioning

confidence: 99%

Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents

Santo¹,

Simard²,

Ramirez³

et al. 2015

CIM

View full text Add to dashboard Cite

Percutaneous coronary intervention is the most commonly performed method of revascularizing obstructive coronary artery disease. The impact of stent strut design on clinical outcomes remains unclear. The Endeavour Resolute (ER-ZES) and the Resolute Integrity (RI-ZES) zotarolimus-eluting stents utilize identical polymers and anti-proliferative agents, differing only in their respective strut design. This study assessed the comparative safety and efficacy of these two stents in unrestricted contemporary real-world practice. Methods: A total of 542 patients were identified, corresponding to 340 ER-ZES and 480 RI-ZES. The primary endpoint was major adverse cardiac events (MACE) defined by a composite of death, nonfatal myocardial infarction and stroke. Secondary endpoints included post-procedural length of stay, in-stent restenosis, target lesion revascularization, target vessel revascularization, coronary artery bypass grafting and stent thrombosis. Results: MACE occurred in 3.2% of the ER-ZES cohort and 5.0% of the RI-ZES cohort (p= 0.43). Adjusted analysis utilizing propensity score-adjusted odds ratio for MACE, was 1.37 (95% CI 0.46-4.07, p=0.57). The mortality rate (0.9% ER-ZES vs. 1.9% RI-ZES, p=0.59), non-fatal MI (2.3% ER-ZES vs. 3.1% RI-ZES, p=0.75) and stroke (0.0% ER-ZES vs. 0.3% RI-ZES, p=0.85) were not different. Additionally, there was no difference in any of secondary outcomes. Conclusions: The clinical performance and safety of both ER-ZES and RI-ZES were not statistically different, despite differences in stent strut design.

show abstract

Section: Discussionmentioning

confidence: 99%

Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents

Santo¹,

Simard²,

Ramirez³

et al. 2015

CIM

View full text Add to dashboard Cite

show abstract

“…The details of cases involving the use side branch of bifurcation two-stent technique and long stents should be further examined because the platform was quite different between SES (closed-cell based rigid platform) and PES (open-cell based), and the longest standard PES (38 mm) was widely used in daily practice (Table 3). Recently, we reported that the TAXUS Liberté stent did not have a statistically beneficial impact on the mid-term (700-day) angiographic outcomes after placement in a daily practice environment compared to the TAXUS Express stent in a study of more than 1,000 patients with de novo coronary stenosis (21). Thus, although the more uniform neointimal distribution was brought about by the improved diffusion of paclitaxel to the vessel wall due to the thinner TAXUS Liberté stent struts compared to TAXUS Express (1, 2), the angiographic ISR rate of the TAXUS Liberté stent was not significantly different from the other first-generation DESs (Cypher BxV, TAXUS Express) after the baseline adjustment (11,21).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, we reported that the TAXUS Liberté stent did not have a statistically beneficial impact on the mid-term (700-day) angiographic outcomes after placement in a daily practice environment compared to the TAXUS Express stent in a study of more than 1,000 patients with de novo coronary stenosis (21). Thus, although the more uniform neointimal distribution was brought about by the improved diffusion of paclitaxel to the vessel wall due to the thinner TAXUS Liberté stent struts compared to TAXUS Express (1, 2), the angiographic ISR rate of the TAXUS Liberté stent was not significantly different from the other first-generation DESs (Cypher BxV, TAXUS Express) after the baseline adjustment (11,21). The difference in the long-term angiographic efficacy (late restenosis and late TLR) between SES and PES should be further examined in future (16).…”

Section: Discussionmentioning

confidence: 99%

“…We also performed the first diabetes mellitus (DM)-specific sub-analysis of these stents. We examined the angiographic lesion-based binary in-stent restenosis (ISR) within 550 days after PES implantation to all-comer de novo coronary stenosis and compared patients with DM with those of SES by adjusting the baselines using our previously described propensity matching score analysis (11,20,21).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Propensity Score-matched Lesion-based Comparison of Mid-term Angiographic Outcomes of TAXUS Liberté with Cypher Bx Velocity Stents for <i>De Novo</i> Native Coronary Stenosis and in Patients with Diabetes

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objective We sought to perform a propensity score-matched lesion-based comparison of mid-term angiographic outcomes of sirolimus-(SES, Cypher Bx Velocity) and paclitaxel-(PES, TAXUS Liberté, the 2nd-generation TAXUS) eluting stents to treat de novo coronary stenosis and, particularly, in patients with diabetes mellitus (DM) in a daily practice environment. Methods The present study was a non-randomized, retrospective, lesion-based, single center study that included 1,287 de novo native coronary stenosis cases after successful SES or PES placement between February 2007 and April 2011. The primary endpoint was angiographic-based binary in-stent restenosis (% diameter stenosis >50 at secondary angiogram) within 550 days of placement. A propensity score-matched analysis was used to adjust the baselines. Results Among 360 baseline-adjusted angiographic lesions followed up in each arm, the incidence of the primary endpoint in the PES group (11.7%, follow-up period: 350±76 days) was not significantly different from that in the SES group (10.3%, p=0.645, 354±81 days, p=0.912). PES was not associated with the primary endpoint by logistic regression analysis (odds ratio: 1.15, 95% confidence interval: 0.68-1.93, p=0.605). In the DM specific sub-analysis, the primary endpoint in the PES group (19.6%) was not significantly different from that in the SES group (12.8%, p=0.105) in 148 baseline-adjusted lesions in each arm. Conclusion The mid-term angiographic outcomes after TAXUS Liberté placement for all-comer de novo native coronary stenosis and in patients with DM were not significantly different from those of SES in a Japanese daily practice environment.

show abstract

“…Ishikawa et al (12) reported the results of a comparative study on the clinical outcomes between Taxus Liberte ® (TAXUS-Lib; Boston Scientific, Natick, MA, USA) and Taxus Express ® (TAXUS-Exp; Boston Scientific). They also reported a similar result that the only difference between these two Taxus stents is the stent design, which implies that the Taxus Liberte ® stent has a thinner strut and greater space to improve uniform drug distribution.…”

Section: Discussionmentioning

confidence: 99%

Three-year clinical outcomes between Endeavor Resolute® and Resolute Integrity® Zotarolimus-Eluting Stents in an Asian population

et al. 2020

View full text Add to dashboard Cite

Comparison of 3-year clinical outcomes between Endeavor Resolute ® and Resolute Integrity ® zotarolimus-eluting stents in an Asian populationObjective: There is a scarcity of comparative studies between Endeavor Resolute ® -zotarolimus-eluting stent (R-ZES) and Resolute Integrity ® -ZES (I-ZES) during long-term follow-up periods. Although the stent alloy and the polymer of these two ZESs are similar, the platform and the design of these two stents are different. This study was conducted to compare the efficacy and safety of these two different ZESs in the all-comer Korean patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period.Methods: This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. In this single-center, retrospective, and all-comer patients' cohort study, a total of 889 patients who underwent PCI with R-ZES (n=394) or I-ZES (n=495) were enrolled. The primary endpoint was the occurrence of major adverse cardiac events (MACEs) defined as all-cause death, nonfatal myocardial infarction (MI), any repeat revascularization including target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR, and the secondary endpoint was stent thrombosis (ST) at 3 years.Results: To adjust for any potential confounders, the propensity score-adjusted multivariable analysis was performed using the logistic regression model (C-statistics=0.689). The cumulative incidence rates of MACEs [adjusted hazard ratio (aHR), 1.341; 95% confidence interval (CI), 0.615-2.922; p=0.461], all-cause death, nonfatal MI, any repeat revascularization, and ST (aHR, 2.090; 95% CI, p=0.571) were similar between the two groups during the 3-year follow-up period. Conclusion: R-ZES and I-ZES demonstrated comparable efficacy and safety after PCI during a 3-year follow-up period. However, these results can perhaps be more precisely defined by other large and long-term follow-up studies in the future.

show abstract

Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Liberté stents for de novo native coronary stenosis

Abstract: The midterm clinical and angiographic outcomes after placement of the new TAXUS-Lib stent for de novo coronary stenosis in a daily practice environment were statistically equivalent compared to the former TAXUS-Exp.

Cited by 4 publications

References 22 publications

Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents

Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents

Propensity Score-matched Lesion-based Comparison of Mid-term Angiographic Outcomes of TAXUS Liberté with Cypher Bx Velocity Stents for <i>De Novo</i> Native Coronary Stenosis and in Patients with Diabetes

Three-year clinical outcomes between Endeavor Resolute® and Resolute Integrity® Zotarolimus-Eluting Stents in an Asian population

Contact Info

Product

Resources

About